Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support
Status:
Not yet recruiting
Trial end date:
2023-03-21
Target enrollment:
Participant gender:
Summary
Hormonal milieu during implantation is crucial to embryo-endometrium interaction and to the
viability of the conceptus. Alterations in the peri-implantation environment are considered
to impair perinatal outcomes in intracytoplasmic sperm injection (ICSI) therapy. GnRH-a is a
new and promising modality for LPS. Regimens for using GnRH-a in LPS, including single
mid-luteal bolus or the addition of a GnRH-a to progesterone supplementation, have been
recently suggested. The aim of this study is to evaluate the impact of addition of mid-luteal
single-dose or multiple-dose GnRH agonist to the routine luteal phase support in patients
undergoing ICSI cycles using GnRH antagonist protocol.